Prolonged Versus Standard-Duration Venous Thromboprophylaxis in Major Orthopedic Surgery

@article{Sobieraj2012ProlongedVS,
  title={Prolonged Versus Standard-Duration Venous Thromboprophylaxis in Major Orthopedic Surgery},
  author={Diana M. Sobieraj and Soyon Lee and Craig I. Coleman and Vanita Tongbram and Wendy T Chen and Jennifer A. Colby and Jeffrey Kluger and Sagar S Makanji and Ajibade O Ashaye and C. Michael White},
  journal={Annals of Internal Medicine},
  year={2012},
  volume={156},
  pages={720 - 727}
}
BACKGROUND The optimal duration of thromboprophylaxis after major orthopedic surgery is unclear. PURPOSE To compare the benefits and harms of prolonged versus standard-duration thromboprophylaxis after major orthopedic surgery in adults. DATA SOURCES Cochrane Central Register of Controlled Trials and Scopus from 1980 to July 2011 and MEDLINE from 1980 through November 2011, without language restrictions. STUDY SELECTION Randomized trials reporting thromboembolic or bleeding outcomes that… 
Effectiveness and safety of different duration of thromboprophylaxis in 16,865 hip replacement patients--a real-word, prospective observational study.
TLDR
In a real-word observational cohort of unselected THR patients, no difference was observed in the risks of symptomatic VTE, VTE/ death or bleeding with respect to thromboprophylaxis duration and direct comparison between benefits and harms did not favor any of the three treatment durations.
Optimal duration of anticoagulant thromboprophylaxis in total hip arthroplasty: new evidence in 55,540 patients with osteoarthritis from the Nordic Arthroplasty Register Association (NARA) group
TLDR
The data indicate that short-term thromboprophylaxis started postoperatively is associated with increased 90-day mortality, with no overall clinically relevant difference in the risks of venous thromboembolism, major bleeding, and death within 90 days of THA with respect to throm bopropholaxis duration.
Thromboprophylaxis after Knee Arthroscopy and Lower‐Leg Casting
TLDR
The results of two parallel, pragmatic, multicenter, randomized, controlled, open‐label trials showed that prophylaxis with low‐molecular‐weight heparin for the 8 days after knee arthroscopy or during the full period of immobilization due to casting was not effective for the prevention of symptomatic venous thromboembolism.
Venous thromboprophylaxis duration and adherence to international guidelines in patients undergoing major orthopaedic surgery: results of the international, longitudinal, observational DEIMOS registry.
TLDR
A gap between real life VTE prophylaxis and the ACCP 2008 recommendations is observed and improved prescription of extended thromboprophylaxis is warranted to ensure adherence to international guidelines.
Thromboprophylaxis only during hospitalisation in fast-track hip and knee arthroplasty, a prospective cohort study
TLDR
The low incidence of symptomatic TEE and VTE suggests that in-hospital prophylaxis only, is safe in fast-track THA and TKA patients with LOS of ≤5 days, and Guidelines on thromboprophylaxis may need reconsideration infast-track elective surgery.
Safety, Efficacy and Cost Analysis of Rivaroxaban versus Fondaparinux for Thromboprophylaxis after Joint Replacement at an Inpatient Rehabilitation Facility
This study compares safety, efficacy, and cost of the new oral Factor Xa inhibitor rivaroxaban to fondaparinux, an injectable anticoagulant, for prevention of VTE (venous thromboembolism) after hip
Low dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study
TLDR
Fixed low dose warfarin started preoperatively is equivalent to two other standards of care under study as VTE prophylaxis for the patients having elective major joint replacement surgery.
Profilaxis tromboembólica en cirugía ortopédica y traumatología
TLDR
Thromboembolism prophylaxis is well-established in major orthopaedic surgery, with low-molecular-weight heparins the most often chosen agent, but direct-acting anticoagulants have been gaining ground and can be used in this scenario (except for hip fracture surgery).
Risk factors and pharmacologic prophylaxis for venous thromboembolism in elective spine surgery.
TLDR
Pharmacologic prophylaxis, primarily with unfractionated heparin, after elective spine surgery was not associated with a significant reduction in VTE, however, there was a significant increase in postoperative hematoma requiring reoperation among patients undergoing proplylaxis.
I nuovi anticoagulanti orali e l’anestesia in chirurgia ortopedica maggiore: cosa sappiamo?
TLDR
Two new oral anticoagulants, dabigatran and rivaroxaban, which have been recently approved in Europe as thromboprophylactic agents for hip and knee arthroplasties, are summary at summarising the main characteristics.
...
1
2
3
4
...

References

SHOWING 1-10 OF 29 REFERENCES
Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study.
TLDR
Extending prophylaxis with warfarin for a few more weeks beyond the hospital stay has the potential to considerably improve the outcome of patients who undergo hip arthroplasty.
Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.
TLDR
Extended prophylaxis with fondaparinux for 3 weeks after hip fracture surgery reduced the risk of VTE by 96% and was well tolerated.
Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)
TLDR
This study shows that prolonged thromboprophylaxis with dalteparin significantly reduces the frequency of DVT and should be recommended for 5 weeks after hip replacement surgery.
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.
TLDR
It is concluded that prolonged (35 days) thrombo prophylaxis with dalteparin is more effective than a standard length regimen without increased risk of bleeding complications or other adverse events.
The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin.
TLDR
Prophylaxis with enoxaparin for one month significantly reduces venous thromboembolic disease in patients undergoing THR compared to conventional prophylactic during hospitalization.
The post-hospital discharge venous thrombosis risk of the orthopedic patient.
TLDR
Perprotocol analysis in 155 patients confirmed that total hip replacement patients have a significant risk of developing DVT after hospital discharge and continued prophylaxis with enoxaparin is effective in reducing this risk.
The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin.
TLDR
Prophylaxis with enoxaparin for one month significantly reduces venous thromboembolic disease in patients undergoing THR compared to conventional prophylactic during hospitalization.
Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement
TLDR
Prolonging enoxaparin thromboprophylaxis following hip replacement for a total of four weeks provided therapeutic benefit, by reducing the prevalence of venous thromboembolism, without compromising safety.
Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials
TLDR
Among patients undergoing total hip or knee replacement, extended-duration prophylaxis significantly reduces the frequency of symptomatic venous thromboembolism and the reduction in risk is equivalent to about 20 symptomatic events per 1000 patients treated.
Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement
TLDR
Fondaparinux after both THR and TKR and extended-duration LMWH after THR appear to be cost-effective prophylaxis regimens, whereas small numbers for other comparisons and absence of trials reporting symptomatic endpoints prohibit comprehensive conclusions.
...
1
2
3
...